| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -32,968 | -6,409 | -40,966 | -95,248 |
| Share-based compensation expense | 2,442 | 673 | 2,000 | 4,232 |
| Accretion expense of deferred royalty obligation | 6,839 | 7,784 | 7,400 | 13,948 |
| Impairment of long-lived assets and prepaid expenses | NaN | NaN | NaN | 6,414 |
| Cumulative catch-up adjustment, deferred royalty obligation | NaN | 22,729 | -321 | -196 |
| Impairment of long-lived assets and prepaid expenses and other related costs | NaN | -545 | 7,240 | NaN |
| Write-downs of inventory | 1,473 | 411 | 237 | 1,636 |
| Depreciation | NaN | 0 | 1 | 704 |
| Amortization of operating lease right-of-use assets | 114 | 113 | 121 | 937 |
| Share of results in joint venture | NaN | 0 | 0 | 0 |
| Warrant obligations, decrease in fair value | -2,227 | NaN | NaN | 0 |
| Amortization of debt discount, senior secured term loan | 225 | 246 | 733 | 841 |
| Other | 603 | 122 | 53 | -479 |
| Accounts receivable, net | 1,928 | 6,187 | -3,266 | 5,868 |
| Inventory | -16 | 853 | 516 | 1,012 |
| Prepaid expenses and other current assets | -2,007 | 215 | 1,602 | -7,050 |
| Other long-term assets | NaN | 0 | -100 | 146 |
| Accounts payable | -3,874 | 932 | -1,290 | -8,680 |
| Accrued expenses and other current liabilities | -3,183 | 1,974 | -799 | -8,595 |
| Operating lease liabilities | -247 | -510 | -992 | -1,002 |
| Other long-term liabilities | 2,204 | -6,720 | 2,225 | 4,085 |
| Net cash used in operating activities | -29,710 | -31,123 | -29,630 | -80,421 |
| Payment for purchases of property and equipment | 32 | 0 | 0 | 264 |
| Proceeds from the sale of equipment | NaN | -659 | NaN | NaN |
| Proceeds from pre-funded warrants, net of transaction costs | NaN | 14,612 | 0 | 50,760 |
| Net cash used in investing activities | -32 | 659 | 0 | -264 |
| Proceeds from the sale of common shares, net of transaction costs | -20 | 43,522 | -479 | 43,239 |
| Proceeds from share issuance under stock purchase plan | 0 | 0 | 0 | 271 |
| Proceeds from the exercise of stock options | 205 | 219 | 281 | 34 |
| Taxes paid related to net settled equity awards | 768 | 1,264 | 0 | 250 |
| Net cash (used in)/ provided by financing activities | -583 | 57,089 | -198 | 94,054 |
| Net decrease in cash and cash equivalents | -30,325 | 26,625 | -29,828 | 13,369 |
| Exchange (losses)/gains on cash and cash equivalents | -5 | -25 | 330 | NaN |
| Cash and cash equivalents at beginning of period | 261,338 | 234,738 | 250,867 | NaN |
| Cash and cash equivalents at end of period | 231,008 | 261,338 | 234,738 | NaN |
ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT)